psoriatic arthritis
FDA Expands Indication for Abatacept to Treat Juvenile Psoriatic Arthritis
The FDA expanded the indication for abatacept for the treatment of patients 24 months of age and older with active ...
NOVEMBER 3, 2023
FDA Approves Pediatric Treatment for Psoriatic Arthritis
The FDA has expanded the use of ustekinumab injection for subcutaneous use to treat pediatric patients 6 years and ...
AUGUST 5, 2022
FDA and ACR to Hold Virtual Summit
The FDA CDER and the ACR will co-host a virtual meeting to discuss patient care, legislative policy and research ...
APRIL 29, 2022
FDA Grants Second Indication for Skyrizi
The FDA granted a new indication for risankizumab-rzaa to treat adults with active psoriatic arthritis.
JANUARY 25, 2022
Upadacitinib Receives FDA Approval for Active Psoriatic Arthritis
The FDA approved 15 mg of once-daily upadacitinib for the treatment of adults with active psoriatic arthritis who ...
DECEMBER 16, 2021
Leveraging the EHR Among Tools for Boosting Biosimilars
Despite the promise of huge savings with biosimilars—an estimated $140 billion in discounted spending over ...
OCTOBER 28, 2021
Multidisciplinary Specialty Care Team Approach Improves Biosimilar Adoption
A multidisciplinary specialty care team approach was significantly more successful in converting patients to ...
NOVEMBER 30, 2020
Despite Deadly Threat, Methotrexate Timing Mix-ups Still Happen
Mistakenly taking oral methotrexate daily instead of weekly can be deadly for patients who have rheumatoid ...
APRIL 17, 2020
FDA Approves Biosimilar for Multiple Rheumatologic Conditions
The FDA approved adalimumab-bwwd, a biosimilar referencing adalimumab, for the treatment of rheumatoid arthritis, ...
AUGUST 28, 2019
Cimzia Receives New Indication for Moderate to Severe Plaque Psoriasis
The FDA approved a new indication for Cimzia to treat moderate to severe plaque psoriasis in adults.
JUNE 8, 2018
